Brief Reports
Copyright ©The Author(s) 2004.
World J Gastroenterol. Feb 15, 2004; 10(4): 610-613
Published online Feb 15, 2004. doi: 10.3748/wjg.v10.i4.610
Table 1 Effect of KCCM or LPS on HSC proliferation (mean ± SD, n = 12)
TreatmentA
LPS (1 μg/ml)0.096 ± 0.003
LPS (10 μg/ml)0.101 ± 0.004
KCCM1 (unstimulated)0.123 ± 0.008c
KCCM2 (1 μg/ml LPS-activated)0.132 ± 0.005a
KCCM3 (10 μg/ml LPS-activated)0.106 ± 0.010d
KCCM1 + anti-TGF-β1 antibodies0.109 ± 0.009b
KCCM2 + anti-TGF-β1 antibodies0.115 ± 0.008d
KCCM3 + anti-TGF-β1 antibodies0.106 ± 0.010
Control group0.100 ± 0.003